Xencor, Inc. (NASDAQ:XNCR) Stake Increased by Amalgamated Bank

Amalgamated Bank grew its holdings in Xencor, Inc. (NASDAQ:XNCR) by 11.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,243 shares of the biopharmaceutical company’s stock after purchasing an additional 2,028 shares during the period. Amalgamated Bank’s holdings in Xencor were worth $465,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of XNCR. KBC Group NV lifted its holdings in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Xencor by 127.3% in the third quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock valued at $2,340,000 after purchasing an additional 65,180 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Xencor in the third quarter valued at $362,000. Intech Investment Management LLC purchased a new stake in shares of Xencor in the third quarter valued at $368,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Xencor by 7.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock valued at $12,609,000 after purchasing an additional 40,788 shares in the last quarter.

Wall Street Analysts Forecast Growth

XNCR has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. StockNews.com lowered Xencor from a “hold” rating to a “sell” rating in a report on Wednesday, February 26th. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Xencor has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Trading Down 2.1 %

Xencor stock opened at $14.15 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market capitalization of $997.04 million, a price-to-earnings ratio of -4.42 and a beta of 0.75. Xencor, Inc. has a one year low of $13.83 and a one year high of $27.24. The company’s fifty day moving average price is $19.03 and its two-hundred day moving average price is $20.68.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.